EMD Millipore launches new kits for use on Gyros’ immunoassay platform
- Simple, automated, nanoliter-scale assays requiring as little as 1 µL of sample
- Ready-to-use kits are fully qualified for reliable use in clinical research
- Accuracy and precision meets or exceeds ELISA performance
March 25, 2014, Uppsala, Sweden — Gyros AB today announced that EMD Millipore, Life Science division of Merck KGaA of Darmstadt, Germany, has released five new immunoassay kits designed specifically for use on Gyrolab™xP workstation. The new, fully qualified GyroMark™ HT kits from EMD Millipore will enable clinical researchers and drug developers to generate valuable research data much faster than typical ELISA kits.
Traditional ELISAs can consume significant time, sample and reagents. With the fully automated, walk-away system from Gyros, up to 480 data points can be generated in a run.
“We are very pleased to be able to partner with Gyros to fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform,” says Jehangir Mistry, PhD, General Manager, Multiplex & Immunoassays at EMD Millipore.
The initial launch includes five assays for important metabolic and toxicity biomarkers, such as GLP-1, Insulin, Clusterin and KIM-1. EMD Millipore plans to release additional kits this year and is offering custom kits for companies who have specific needs or unique or novel antibodies.
Because the Gyrolab platform employs microfluidic technology with parallel processing, it offers many advantages over traditional assays in addition to reagent and time savings. GyroMark HT assays provide:
- accuracy over a four-log dynamic range (compared to two logs for ELISAs,
- elimination of cross-talk and plate position artifacts
- simplified sample prep (only 1:2 dilution necessary) with reduced matrix interference
Gyros’ Global Marketing Director Maria Hjortsmark commented: “Gyrolab system revolutionizes immunoassays, enabling scientists to analyze large numbers of samples in parallel, at nanoliter scale and using a fully automated system. We are delighted that EMD Millipore has now chosen to work with us to develop off-the-shelf kits, to further reduce time to results, freeing up analyst time and offering an easier route to robust, reproducible data.”
For more information on these new kits, please contact Cindy Fry, BS, MBA, EMD Millipore, +1 636-720-1078, firstname.lastname@example.org.
Leslie Eisenberg, Feinstein Kean Healthcare, 617-244-3872, email@example.com
For Gyros AB
Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: firstname.lastname@example.org / email@example.com
Notes to editors:
About Gyros (www.gyros.com)
Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The Gyros™ immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.
Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.
The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.